StockData
Arrowhead Pharmaceuticals, Inc. logo

Arrowhead Pharmaceuticals, Inc. (ARWR) stock

ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-K on Nov 12, 2026Score 5/3035% above fair value
$43.11+0.12 (+0.28%)

Close on Nov 18, 2026Market cap $6.09BP/E –Yield –

Earnings

Arrowhead Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 4, 2027
Q1 FY2027 · estimated, during market hours
Revenue, Q3 FY2026
$75.25M
+171.0% on a year earlier
EPS, Q3 FY2026
-$1.36
-$1.26 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Arrowhead Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q1 FY2027ended Dec 31, 2026Feb 4, 2027Expected––––
Q4 FY2026ended Sep 30, 2026Nov 12, 2026after the close–––Release
Q3 FY2026ended Jun 30, 2026Aug 4, 2026during market hours$75.25M+171.0%-$1.36Release
Q2 FY2026ended Mar 31, 2026May 7, 2026during market hours$73.74M–-$0.93Release
Q1 FY2026ended Dec 31, 2025Feb 5, 2026during market hours–––Release
Q4 FY2025ended Sep 30, 2025Nov 25, 2025during market hours–––Release
Q3 FY2025ended Jun 30, 2025Aug 7, 2025during market hours$27.77M–-$1.26Release
Q2 FY2025ended Mar 31, 2025May 12, 2025during market hours–––Release
Q1 FY2025ended Dec 31, 2024Feb 10, 2025during market hours$2.50M-29.6%-$1.39Release
Q4 FY2024ended Sep 30, 2024Nov 26, 2024during market hours–––Release
Q3 FY2024ended Jun 30, 2024Aug 8, 2024during market hours––-$1.38Release
Q2 FY2024ended Mar 31, 2024May 9, 2024during market hours––-$1.02Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Arrowhead Pharmaceuticals has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Arrowhead Pharmaceuticals puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Arrowhead Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. News
  6. Update
  7. Update
  8. Results
  9. News
  10. News
  11. News
  12. News
  13. News
  14. Results
  15. Results

See a number that looks wrong?